GlassScriptPhysician profile
David R Lovett
NPI 1790753283
$3,200.49
in general payments reported to CMS, 2019-2025
20 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2021: $110 · 2022: $798 · 2023: $508 · 2024: $201 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $729.29 | 2019-2024 | Reblozyl, Opdivo |
| Janssen Biotech, INC. | $280.99 | 2022-2025 | Carvykti, Rybrevant, Darzalex |
| Genentech USA, INC. | $247.15 | 2019 | |
| Clovis Oncology, INC. | $219.71 | 2019 | |
| Puma Biotechnology, INC. | $193.07 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $178.29 | 2019-2021 | |
| Glaxosmithkline, LLC. | $165.52 | 2022 | |
| Incyte Corporation | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $124.90 | 2025 | Keytruda |
| Seagen INC. | $120.26 | 2023 | Padcev |
| Karyopharm Therapeutics INC. | $114.30 | 2023 | Xpovio |
| Celgene Corporation | $112.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.78 | 2023 | Ninlaro |
| Pharmaessentia USA Corporation | $95.25 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $90.49 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $87.78 | 2019 | |
| Exelixis INC. | $85.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $67.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.00 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lovett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.